跳至主要内容
临床试验/NCT04972799
NCT04972799招募中不适用

AUTOGRAFI : Evaluation of the Efficacy and Safety of Autologous Fat Injection Into the Intersphincter Space in Fecal Incontinence: a Randomized, Placebo-controlled, Cross-over, Double-blind Trial

Rennes University Hospital3 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2022年10月19日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
50
试验地点
3
主要终点
Number of fecal incontinence events

研究概览

简要总结

Fecal incontinence is frequent and has a significant impact on the quality of life of individuals. Its therapeutic management is based primarily on transit regulation and rehabilitation and secondarily on neuromodulation of the sacral roots. However, this strategy is insufficient in more than one patient out of three. The patient and the clinician are often at a loss and the therapeutic possibilities are limited to the use of evacuating enemas and/or a colostomy.

The practice of autologous fat injections was initially developed in plastic surgery. The studies that have evaluated the efficacy of autologous fat injections in fecal incontinence in men are preliminary and old isolated observations. However, they have shown an improvement in episodes of fecal incontinence and in sphincter parameters. In the field of proctology and autologous fat injections, 2 recent small open studies have evaluated the efficacy and morbidity of this therapy in the treatment of anal fistulas related to Crohn's disease.

The primary hypothesis of the work is that autografting adipose tissue into the intersphincteric space can decrease episodes of fecal incontinence in patients with severe fecal incontinence due to sphincter failure. The secondary hypotheses are that autograft of adipose tissue in the intersphincter space improves resting anal pressures, is a well-tolerated technique for patients, and may improve their quality of life.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age or older
  • severe fecal incontinence characterized by at least one episode of weekly fecal incontinence
  • failed rehabilitation and dietary management strategies
  • who have failed/contraindicated/refused sacral root neuromodulation (in the indication of fecal incontinence)
  • having, for women of childbearing age, effective contraception throughout the study
  • having given free, informed and written consent

排除标准

  • unable or unwilling to undergo follow-up or symptomatic evaluation
  • contraindication to general anesthesia
  • contraindication to metronidazole (hypersensitivity and wheat allergy)
  • significant pelvic static disorder
  • active anal suppuration
  • anal stenosis
  • externalized rectal prolapse
  • chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis)
  • on anticoagulants or antiaggregants
  • history of anal or rectal neoplasia
  • coagulation anomaly, curative anticoagulation
  • history of rectal surgery
  • history of pelvic radiotherapy
  • previous treatment with inert materials (hyaluronic acid, biosilicones, coaptitis) in the 5 years preceding inclusion
  • allergy to lidocaine or contraindication to adrenaline
  • protected person (adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty, pregnant or breast-feeding woman, minor)
  • participating in another interventional trial concurrently
  • not covered by a social security system

结局指标

主要结局

Number of fecal incontinence events

时间窗: 3 months

Change from baseline in number of fecal incontinence events at 3 months

次要结局

未报告次要终点

研究者

发起方
Rennes University Hospital
申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验